RLMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Relmada Therapeutics Inc (RLMD) does not present a strong buy opportunity for a long-term beginner investor at this time. While the stock shows some positive technical indicators and insider buying, the company's financial performance is weak, and there are no strong proprietary trading signals or significant near-term catalysts to justify immediate investment. The stock's potential for growth is tied to its drug pipeline, which is still in development and carries inherent risks. For a long-term investor, it may be better to monitor the stock for further developments or improved financial performance.
The technical indicators are mixed but slightly positive. The MACD is above 0 and expanding positively, indicating bullish momentum. The RSI is in the neutral zone at 71.283, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 4.545), suggesting limited immediate upside potential. The stock has a 40% chance of declining slightly (-2.13%) in the next day.
Analysts have upgraded the stock with a price target of $8-$9, citing the potential of its lead asset NDV-01 in addressing a $2.3B market.
Insiders are buying, with a 1133.44% increase in buying activity over the last month.
The stock has bullish moving averages, indicating positive momentum.
Weak financial performance in Q3 2025, with net income dropping by -53.55% YoY and EPS declining by -58.33%.
No recent congress trading data or significant political endorsements.
The stock has a 40% chance of slight declines in the short term, with no immediate proprietary trading signals.
The company's financial performance in Q3 2025 was weak, with no revenue growth, a net income drop of -53.55% YoY, and a significant decline in EPS (-58.33%). Gross margin remains at 0%.
Analysts are optimistic about the company's long-term potential, with upgrades to 'Outperform' and 'Buy' ratings and price targets of $8-$9. They highlight the potential of NDV-01 in addressing a $2.3B market, but this is contingent on successful development and commercialization of the drug.
